In Brief: BMS' ConvaTec
This article was originally published in The Gray Sheet
BMS' ConvaTec: Bristol-Myers Squibb division's infection control and contamination control businesses are for sale, BMS announces Aug. 14. The businesses, which make cleaners and sterilants used by health providers and FDA-regulated manufacturers, "have performed well but do not meet the strategic objectives" of the company, BMS says. The firm acquired the units through its January 1995 purchase of Calgon Vestal Laboratories from Merck ("The Gray Sheet" Nov. 7, 1994, I&W-1). Wound management and "certain other products" acquired in that deal will remain with ConvaTec...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.